BIG
DSGN icon

Brooklyn Investment Group’s Design Therapeutics DSGN Stock Holding History

Brooklyn Investment Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19
Closed -$65 – 1234
2025
Q2 		$65 Hold
19
– – ﹤0.01% 3257
2025
Q1 		$74 Buy
+19
New +$91 ﹤0.01% 2711

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Brooklyn Investment Group's DSGN Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Design Therapeutics (DSGN) in Q3 2025, closing a stake of 19 shares — an estimated $65 sold.

Brooklyn Investment Group first reported a position in DSGN in Q1 2025 and held it in 2 quarters. The position peaked at $74 in Q1 2025. 95 funds tracked by Wall St. Rank hold DSGN as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Design Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 19 Design Therapeutics shares in Q3 2025, an estimated $65.
  • Brooklyn Investment Group first reported a position in Design Therapeutics in Q1 2025 and held it in 2 quarters.
  • Brooklyn Investment Group's Design Therapeutics position peaked at $74 in Q1 2025.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.